• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The current invention relates to an automated process for the production of formulations comprising antibodies against Respiratory Syncytial Virus (RSV) comprising the steps of culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor to a supply of culture medium and of gas or gas mixture; fluid connection of said bioreactor to a downstream unit; and growing cells to a density of at least 50 million cells per ml. The total volume of the bioreactor is at least 10 liters. The invention also provides a suitable system for implementing the method. The system is a small scale cabinet size system and can be placed in a clean transportable chamber.
    公开号:BE1022441B1
    申请号:E2015/5063
    申请日:2015-02-09
    公开日:2016-03-30
    发明作者:José Castillo
    申请人:Univercells Sa；
    IPC主号:
    专利说明:

    System, apparatus and method for anti-RSV formulations and antibodies
    Technical Field The invention relates to methods and systems for producing and / or purifying cells or cell products, such as proteins or peptides. More particularly, the invention provides methods and systems for producing and / or purifying formulations and / or anti-RSV antibodies.
    Background
    Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory disease in infants and children. The annual epidemic nature of RSV infection is obviously global, but the incidence and severity of RSV-related disease in a given season varies by region. In temperate regions of the northern hemisphere, it usually begins in late fall and ends in late spring. It is estimated that RSV-related illness results in 90,000 hospitalizations and causes 4,500 deaths per year in the United States. Primary RSV infection occurs most often in children 6 weeks to 2 years of age and unusually in the first 4 weeks of life during nosocomial outbreaks.
    Treatment options for an established disease due to RSV are limited. Serious illness due to RSV of the lower respiratory tract often requires considerable symptomatic treatment, including administration of humidified oxygen and respiratory support. Currently, the only approved approach to the prophylaxis of RSV disease is passive immunization. A humanized antibody directed to an epitope in the antigenic A site of the RSV F protein, palivizumab, is approved for intramuscular administration to pediatric patients for the prevention of severe lower respiratory disease caused by RSV. Because of the high incidence of RSV and the resulting serious risks for infants and newborns, there is a need for a more cost-effective and efficient way to produce antibodies and / or anti-RSV formulations, especially for developing countries.
    Conventionally, the production of antibodies or antibody fragments, such as palivizumab, involves culturing and / or isolating cells and / or purifying secreted products by cells. These conventional approaches require many manual manipulations that are subject to variations even if they are conducted by skilled technicians. When used on the scale necessary to produce large quantities of product, the rate of variability, error, or contamination may become unacceptable for commercial processes.
    Production of cell-secreted products can be achieved by using a bioreactor (fibers, microfibers, hollow fiber, ceramic composite material, fluidized bed, fixed bed, etc.) or by using a stirred tank. This increases the concentration of product. Currently available systems are versatile in nature and require considerable time for trained operators to install, load, empty, inoculate, operate, collect and unload.
    The prior art uses a large scale plant in which cells are cultured in batch bioreactors, for example 10,000 liters (L). After a culture period, the batch antibodies are collected within about 8 hours. As a result, the 10,000 L suspension is clarified, the medium is exchanged (the cell culture medium is replaced by a buffer medium) by diafiltration, and the compounds are separated or purified by chromatography. An additional filtration step may follow. Disadvantages of the prior art include the use of a large filter, a large amount of buffer medium, a large chromatography column and a considerable amount of purified water. These amounts represent a considerable cost in terms of production of purified water and water storage. A major drawback is the loss of yield in the clarification step which is an essential step of this installation to obtain a diafiltration which is effective enough to exchange the cell culture medium within the limit of 8 hours.
    Another disadvantage of the current available systems is the large investments that are required in terms of necessary facilities, space requirements, etc. (the "material") but also in terms of the material needed to produce the desired biomolecules or cell products. In addition, the necessary energy input weighs heavily on the required budget. As a result, the enormous investments required put a restriction on further development in the field of therapeutic antibody production, not only in the US and Europe, but also in developing countries.
    WO 2012/170130 describes an automated integrated system comprising a cell growth unit and a purification unit. The system is still quite demanding in operation and requires additional optimization measures to improve usability and to increase the output particularly when said system is not scalable.
    Accordingly, there is a need for systems and methods by which cells and / or cell products can be cultured and if desired purified in a fully automated, rapid and sterile manner. In addition, there is a need for a methodology and system that provides high product output at minimal capital cost and CAPEX investments and reduced OPEX.
    The object of the current invention is to provide methods and systems for the production of cells and / or cell products, particularly anti-RSV antibodies, which overcome at least some of the aforementioned disadvantages and disadvantages. An object of the invention is to provide automated and integrated methods and systems for the growth and maintenance of cells, but also for multiple variable downstream applications such as the collection and / or purification of cells and / or cellular products. especially anti-RSV antibodies. Another object of the present invention is to provide anti-RSV formulations. Summary of the invention
    In a first aspect, the present invention provides an integrated automated method for the production of biomolecules such as proteins or peptides, particularly for the production of antibodies against RSV. The method comprises the steps of culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor to a culture medium feed and a gas or gas mixture; fluid bonding said bioreactor to a downstream unit; and culturing cells at a density of at least 50 million cells per ml. Preferably, the total volume of the bioreactor is at least 10 liters. In a preferred embodiment, the method of the present invention further provides anti-RSV formulations comprising anti-RSV antibodies.
    In a second aspect, the present invention provides a suitable system for carrying out the method of the invention. The system is a small-scale system the size of a cabinet and can be placed in a clean transportable room. In a preferred embodiment, the invention provides a system for the production of biomolecules such as proteins or peptides, particularly for the production of antibodies against RSV. The system includes a cell culture unit and a downstream unit that are fluidly connected to each other. Said cell culture unit comprises at least one perfusion bioreactor, which makes it possible to cultivate cells at a density of at least 50 million cells per ml, and a feeding means for supplying said bioreactor with a cell medium and a gas or a gas mixture. The system is characterized in that the total volume of the bioreactor is at least 10 liters. In a preferred embodiment, the method of the present invention further provides anti-RSV formulations comprising anti-RSV antibodies.
    Conventionally, in order to manage the production of a large quantity of therapeutic products, such as antibodies against RSV, a considerable number of large instruments (such as large bioreactors, large filters, large chromatography columns by purifications, etc.). ) is necessary. The compactness of the design and the amount of support resources have, however, become an important issue. Bearing large units becomes a logistical problem for the system. The system of the present invention has no such requirement particularly because of the use of a small bioreactor and the subsequent processing of a predefined small volume of supernatant. The present method and system are free from manual manipulation, thereby substantially reducing the risk of contamination.
    Cell products such as antibodies are currently produced in large scale equipment. The cells are usually cultured for about 20 days in a considerable volume of about 10,000 L culture medium. After this, the cell culture is stopped and the considerable volume of culture medium is then processed to extract the desired molecule. The equipment is rather expensive and its cost is about $ 100 million.
    The present invention provides methods and systems in which cells are cultured at a high density. Preferably, said high density culture is performed in a small bioreactor with continuous infusion. More preferably, a high density culture is maintained in the bioreactor. The systems and methods of the invention provide an automated, integrated and continuous chain of operations starting with cell growth to obtaining the desired product which may be cells or cell products such as antibodies. In a preferred embodiment of the invention, after reaching a predetermined cell density within the bioreactor, a predefined small volume of supernatant is further processed in the downstream unit of the system. The treatment of the supernatant, in the predefined small volume, is performed while maintaining the high cell density culture within the bioreactor. By supernatant, reference is made to the culture medium that is inside the bioreactor during cell culture.
    Among other advantages, the systems and methods of the invention provide for the production of cells and / or cell products in high yield, particularly antibodies against RSV, compared to prior art methods and systems reducing this makes the costs of the final product. The systems and methods of the invention also allow the production of cells and / or cell products using a smaller amount of purified water than the prior art systems and methods. The present invention provides fully automated and integrated systems that are cheaper and cost at least 5 to 6 times less than conventional large scale systems. This ultimately leads to a lower cost of investment and production, which is a considerable advantage, for example by targeting manufacturing for Third World countries. The invention makes it possible to provide Third World countries with national production systems and also enables pharmaceutical companies without a history of biotechnology to mass produce cellular products such as antibodies, in particular antibodies against RSV.
    Description of figures
    Figure 1 shows an embodiment of a bioreactor of the invention; Figure 2 shows an embodiment of the cell culture unit of the invention; FIG. 3 represents the culture unit C which is connected to fluid to a downstream unit D comprising a collection means according to one embodiment of the invention; FIG. 4 represents the culture unit C which is fluidly connected to a downstream unit D comprising a filtration means and a collection means according to one embodiment of the invention; FIG. 5 represents the culture unit C which is fluidly connected to a downstream unit D comprising a filtration means and a purification means according to one embodiment of the invention; Figure 6 shows the difference between prior art methods used for the production of biomolecules and the method of the present invention.
    Detailed description of the invention
    The present invention relates to a method and system for the production of anti-RSV antibodies and / or anti-RSV formulations comprising anti-RSV antibodies. The invention specifically aspires to provide a method having an optimum yield in terms of material input and product output. The present invention aspires to provide a fully integrated and automated methodology and system for the production of anti-RSV antibodies and / or anti-RSV formulations comprising anti-RSV antibodies.
    Unless otherwise stated, all terms used in the disclosure of the invention, including technical and scientific terms, have the meaning as generally understood by the ordinary skilled artisan to whom this invention belongs. With additional guidance, term definitions are included to better appreciate the teaching of the present invention.
    As used in this document, the following terms have the following meanings: "One," "an," and "the" as used herein refer to both singular and plural referents unless the context say something else clearly. For example, "a compartment" refers to one or more compartments. "About" you! as used in this document with reference to a measurable value such as a parameter, a quantity, a time duration, and so on, means to encompass variations of +/- 20% or less, preferably +/- 10% or less, more preferably +/- 5% or less, even more preferably +/- 1% or less, and still more preferably +/- 0.1% or less of and from the specified value, provided that such variations are appropriate to perform in the disclosed invention. However, it will be understood that the value to which the "about" modifier refers is also specifically disclosed. "Understand", "understand", and "understand" and "consist of" as used in this document are synonymous with "include", "include", "include" or "contain", "contain", "contains" and are inclusive or open terms that specify the presence of, for example, a component and do not exclude or exclude the presence of components, features, elements, members, additional steps, not mentioned, known in the art or revealed within it.
    Mentioning numeric ranges by a value box includes all numbers and fractions within that range, as well as the framing values mentioned. The term "% by weight" (percent by weight), herein and throughout the specification unless otherwise stated, refers to the relative weight of the respective component based on the total weight of the formulation.
    In a first aspect, the present invention provides an integrated automated method for the production of anti-RSV antibodies. In a preferred embodiment, the method of the invention is suitable for use by a system comprising a cell culture unit. and a downstream unit. The cell culture unit comprises at least one bioreactor for cell growth and / or. the production of cellular products. The downstream unit may comprise different components or a suitable means for further processing of the supernatant, cultured cells and / or cellular products, i.e., anti-RSV antibodies. The method and system of the present invention further provide the production of anti-RSV formulations comprising anti-RSV antibodies. Preferably, said anti-RSV formulations comprise palivizumab, motavizumab, MEDI-557 or any combination thereof.
    For the purpose of the current invention, the term "palivizumab" should be understood as a monoclonal antibody produced by recombinant DNA technology and used in the prevention of Respiratory Syncytial Virus (RSV) infections. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the antigenic A site of the RSV F protein. In two phase III clinical trials in the pediatric population, palivizumab reduces the risk of hospitalization due to RSV infection by 55% and 45%. Palivizumab is dosed once a month by intramuscular (IM) injection, to be administered throughout the duration of the RSV season. Palivizumab is also known under the trademark Synagis®. The term "motavizumab" should be understood as a humanized monoclonal antibody for the prevention of respiratory syncytial virus infection. The term "MEDI-557" should be understood as a humanized monoclonal antibody for the prevention of respiratory syncytial virus infection.
    Preferably, the method of the current invention comprises the steps of culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor to a culture medium feed and to a gas or a gaseous mixture ; fluid bonding said bioreactor to a downstream unit; and culturing cells at a density of at least 50 million cells per ml. Preferably, the total volume of the bioreactor is at least 10 L. At least one sensor is preferably provided for measuring the cell density within the bioreactor.
    In a preferred embodiment, the total volume of bioreactor is at least 10 L, preferably at least 20 L, more preferably at least 30 L, even more preferably at least 40 L, most preferably at least 50 L. The total volume of the bioreactor is at most 1000 L, preferably at most 900 L, more preferably at most 800 L, even more preferably at least at most 700 L, most preferably at most 500 L, even more preferably 500 L. In a further preferred embodiment, the total volume of bioreactor is at most 400 L, preferably at least plus 300 L, more preferably not more than 250 L, most preferably not more than 100 L Total volume of bioreactor refers to the total volume of liquid that can be introduced into the bioreactor, which will then be full.
    Preferably, the volume of culture medium supplied to the bioreactor for culturing cells is sufficient to fill about half of the total volume of said bioreactor. For example, if the total volume of the bioreactor is 1000 L then 400 to 700 L, preferably 450 to 600 L, more preferably 480 to 500 L or any value within the ranges mentioned are provided to the bioreactor for cell culture. Preferably, for the production of antibodies, the bioreactor comprises at least 80 L, preferably at least 90 L, more preferably at least 100 L of culture medium and at most 200 L, preferably at most 180 L, more preferably at most 150 L, even more preferably at most 140 L and most preferably about 125 L of culture medium.
    In a preferred embodiment, cells (mammalian or insect cells) and a suitable culture medium are introduced into the bioreactor. A suitable culture medium refers to the composition of the medium that is required for cell growth. Said compositions are known to those skilled in the art and generally include salts, vitamins, amino acids, sugars, or any combination thereof. The culture medium is preferably supplied to the bioreactor from an outer container of culture medium, i.e. not contained in the system of the invention. From said outer container, the culture medium is directed to an internal reservoir of culture medium, i.e., positioned within the system. Preferably, the culture medium is preheated before being supplied to the bioreactor. More preferably, the culture medium is heated in the internal reservoir of culture medium. The preheating temperature of the culture medium is 20 to 40 ° C, preferably 25 to 38 ° C, more preferably 30 to 37 ° C. In a most preferred embodiment, said culture medium is preheated to about 37 ° C.
    In a preferred embodiment, a waste collection container is provided in which metabolic waste is removed from the bioreactor. Those skilled in the art are aware of such containers and the fittings required to ensure the removal of waste.
    In a preferred embodiment, a mixture of culture medium and gas, such as pure oxygen, or a mixture of culture medium and a gaseous mixture comprising oxygen, is supplied to the bioreactor via a delivery line. single feed or through an inlet to said bioreactor. The use of a single supply line simplifies installation of the system and process as it reduces the required number of fittings and tubing.
    Cells require oxygen during their growth phase in order to have optimal growth. The bioreactor can be moved, thereby increasing oxygen transfer by a factor of at least 10 compared to conventional methods. The operation of the bioreactor at the equilibrium gas is therefore achieved. This in turn increases cell growth, which has a positive impact on the production of biomolecules. Also, operating at constant gas balance, all control units or sensor devices can be omitted, providing a straightforward and simple methodology. In addition, a sensor failure is no longer a problem, and the repairs that were required in prior art systems due to said sensor failure are no longer required, leading to a high reduction in personnel and service costs. operation. The movement of the bioreactor may include, but is not limited to, rotation along a horizontal axis, rotation along a vertical axis, rocking motion along an inclined or tilted horizontal axis of the bioreactor, or any combination of these.
    In a preferred embodiment, the cells are cultured in the bioreactor for a period of time which may vary from a few hours to several days depending on the cells cultured. The cultivation time period is at least 4 hours, at least 10 hours, at least 24 hours, at least 5 days, at least 7 days or any intermediate time. The cultivation period is not more than 70 days, not more than 60 days, not more than 50 days, not more than 40 days, not more than 25 days, not more than 20 days, not more than at most 10 days or any intermediate time.
    Depending on the final product, viral transduction or the introduction of viral vectors may be used. Viral replication competent vectors or replicons have been used for a long period of time as an alternative expression system to increase the yields of therapeutic proteins in mammalian cells. The target gene (s) can be expressed under the transcriptional control of viral promoters so that mRNAs accumulate at extremely high levels in the cytoplasm after transfection and when replication, giving large amounts of target proteins. The viral infection can lead to a transduction process without lysis of the cultured cells or lysis of the cultured cells thereby providing the contents of the cells in the supernatant of the bioreactor.
    Alternatively, hybridoma cells or stably transfected cells may be cultured to produce the desired protein or peptide as an antibody or an antibody fragment.
    Examples of viral replication systems include, but are not limited to, polyoma viruses, lentiviral systems, retroviral systems, adenoviral systems, adeno-associated viruses. Examples of preferred cells used in the current system include, but are not limited to, Vero cells, Hek293T cells, COS cells, CHO cells. In a preferred embodiment of the invention, CHO cells are used.
    In a preferred embodiment of the current invention, the completed medium of the bioreactor is transferred from the bioreactor to or collected in the downstream unit. It will be understood that the bioreactor and the downstream unit are fluidly connected to each other. A pump could be provided to transfer the supernatant to the downstream unit. A preferred embodiment of the C cell culture unit is shown in FIG. 2. The bioreactor 1 comprising the cell culture medium 2 is connected to an internal reservoir of culture medium 3. Said connection is provided by minus an intake manifold 4 and an inlet of the bioreactor 1. Preferably, the internal reservoir of culture medium 3 is supplemented with culture medium from an external container of culture medium (not shown) which is positioned outside the system of the invention the size of a cabinet. Said outer container of culture medium comprises up to 10,000 L, preferably up to 20,000 L of culture medium which is maintained at ambient temperature, i.e. about 20 ° C. The culture medium is preferably preheated in the internal reservoir of culture medium 3 at a temperature of about 37 ° C.
    The completed culture medium, also referred to as supplemented medium in this document, refers to the supernatant of the bioreactor which may comprise a culture medium and / or cultured cells and / or their products. The supernatant of the bioreactor may be free of cells and / or their products. The cell product refers to biomolecules such as proteins, peptides, antibodies, produced by cells and / or any other cellular biomolecules derived from lysis of cells such as cell membranes.
    At least one pump may be provided to ensure the transfer of cell medium from the tank 3 to the bioreactor 1. Preferably, the medium transfer is carried out continuously and / or at a constant rate and / or at variable rates. Said transfer of medium may also be carried out discontinuously and / or at a constant rate and / or at variable rates. To connect the cell culture unit C to a downstream unit or other unit or device, at least one outlet line 5 which is attached to an outlet of the bioreactor 1 is provided. A control box 9 may be provided in the C cell culture unit to control the physical and / or chemical parameters of the supernatant collected from the bioreactor. The downstream unit may comprise a filtering means and / or a collection means and / or a dialysis means and / or a means for purifying biomolecules such as the purification of antibodies. In its simplest form, said downstream unit comprises only a means for collecting the desired finished product, without any prior filtration / purification / dialysis step. The downstream unit components are easily connected to or disconnected from said unit and can therefore be easily replaced, cleaned or sterilized. The downstream unit may be customized according to the needs and wishes of the users and may be powered by a combination of any of the previously mentioned units. Thus, the user is provided with multiple finished product possibilities, cells, filtered cells, filtered cell products, purified cellular products or biomolecules. The user can choose and connect the different downstream compartments according to the desired end product.
    In a preferred embodiment, the downstream unit receives a supplemented medium or medium supplemented with biomolecules from said bioreactor in the continuous mode. Preferably, the downstream unit receives at most 1000 ml / min of medium supplemented with biomolecules from said continuous mode bioreactor. Preferably, the transfer of the supplemented medium is initiated when a predetermined cell density is reached within the bioreactor. Said predetermined cell density is at least 30 million / ml, preferably 40 million / ml, more preferably 50 million / ml, most preferably 60 million / ml. In a preferred embodiment, in parallel with the transfer of the supplemented medium from the bioreactor to the downstream unit, the culture medium is added from the internal reservoir of culture medium to said bioreactor as to maintain the initial volume of medium of the culture medium. culture in the bioreactor. For example, if at the beginning of the process the bioreactor contained 80 L of culture medium, once the media transfer from the bioreactor to the downstream unit is initiated, new culture medium is added to the bioreactor in sufficient volume. so as to maintain a volume of 80 L in said bioreactor. If the transfer of supplemented medium from the bioreactor to the downstream unit is carried out in continuous mode, the addition of new culture medium from the internal reservoir of culture medium into the bioreactor will also be carried out in continuous mode. The method and system of the present invention thus allow the treatment of the completed culture medium in the downstream unit in parallel with the growth of the cells in the bioreactor. This provides several advantages over processes in which cells are cultured in large bioreactors containing large volumes of cell culture followed by stopping said cell culture after a certain period of time or reaching a certain concentration and then starting the downstream processes of the large volume of cell culture. Among other advantages, there can be mentioned a considerable increase in yield and thus a considerable reduction in cost.
    In a preferred embodiment, the medium supplemented with biomolecules received by the downstream unit undergoes at least one process selected from the group consisting of filtration, harvesting, dialysis, biomolecule purification and protein concentration or any combination of these.
    The collection of supplemented medium is preferably carried out continuously at a small volume flow rate. Said volume flow rate is at least 100 ml / min, preferably at least 150 ml / min, more preferably at least 200 ml / min, most preferably at least 250 ml / min. Said volume flow rate is at most 1000 ml / min, preferably at most 800 ml / min, more preferably at most 600 ml / min, most preferably at most 400 ml / min. The supernatant collection can also be carried out in a discontinuous manner. The collected supernatant is then subjected to subsequent treatment selected from a simple collection, filtering, purification of molecules, storage or any combination thereof. The treatment of small volumes of supplemented medium greatly reduces the yield loss and improves the quality and the efficiency of treatment, for example a better filtration and / or purification quality. Moreover, no increase in scale of the operations carried out in the downstream unit is required thus avoiding spending time and money to proportionally increase said operations.
    The continuous collection mode of the present invention may be initiated by the operator based on the product concentration. The collection continues until a preprogrammed time interval has elapsed or until the operator manually completes the collection using a user interface provided in the system of the invention.
    Figure 6 shows the difference between prior art methods used for the production of biomolecules and the method of the present invention. In prior art methods, the cells are cultured for a period of time or until a certain concentration is achieved as shown by curve P of Figure 6. After that, the cell culture is stopped and the downstream processes of Large volume of cell culture can be started and some steps like clarification should be done in about 8 hours. As previously mentioned, this methodology leads to a significant yield loss and is rather expensive. The method of the present invention begins with culturing cells at a high density of at least 50 million cells. Once the required density is reached, the cell culture is maintained over time (curve I in FIG. 6) and a downstream treatment of the supernatant is initiated (I0 in FIG. 6). Said downstream treatment is performed on predefined amounts of supernatant and is repeated after fixed or non-fixed time intervals (Ii to Ix in Figure 6). The downstream treatment is selected from filtration and / or collection and / or dialysis and / or purification of biomolecules or any combination thereof. The method of the present invention thus allows a considerable increase in yield, a considerable reduction in cost while using small equipment requiring less space and easier to maintain.
    In a preferred embodiment, the cultured cells are infected and then ruptured / lysed at a location designed for this purpose in the downstream unit. The supernatant comprising the cell debris and the desired products is then collected using the collection means from the bioreactor. Collection rates are as previously mentioned. The supernatant can be collected and stored for later use in a bag provided in the downstream unit as previously mentioned. The collected supernatant may be subjected to filtration using filtration means prior to storage in a bag of the downstream unit. Alternatively, the recovered supernatant may be filtered and / or subjected to a purification step to separate a specific molecule, such as an antibody, from said supernatant.
    Figure 3 shows an embodiment of the system that is designed to collect cells or a bulk finished product. The culture unit C is fluidly connected to the downstream unit D via the outlet pipe 5. The culture unit C is as previously described. A pump, or collection means, may be provided to collect the supernatant from the bioreactor. The pump can be programmed for example to start supernatant collection from a predefined period of time from the beginning of the culture. The pump may be programmed to collect a predetermined volume of supernatant in an automated continuous mode. The collected supernatant is directed to a collection bag or reservoir 6 wherein said supernatant will be stored for subsequent applications.
    Figure 4 shows an embodiment of the system that is designed for collection and filtering. The culture unit C is fluidly connected to the downstream unit D via the outlet pipe 5. The culture unit C is as previously described. The outlet tubing 5 directs the supernatant to a filtering means 7. A pump, or collection means, may be provided to collect the supernatant from the bioreactor. The pump can be programmed to begin supernatant collection from a predetermined time period from the start of the culture. The pump may be programmed to collect a predetermined volume of supernatant in an automated continuous mode. The collected supernatant is filtered by the filtering means and the filtered supernatant is directed and / or stored in a collection bag or reservoir 6 for use in subsequent applications.
    Purification can be performed using a purification means of the downstream unit. Said means may be an automated means for obtaining a purified biological product such as a protein (e.g., a purified antibody) from the supernatant (e.g., an aqueous medium containing a protein) and collected as previously mentioned . In a preferred embodiment, the purification means comprises at least one or any combination of the following: a selection device such as a purification chromatography column (affinity purification, ion exchange, etc. .), a sequence of purification columns or membrane absorbers, at least one liquid reservoir, a device for flowing the liquid from the reservoirs and in the selection device, a device for diverting the effluent from the selection device. The purification means is capable of being installed in the small-scale system of the invention of cabinet size via a simple or "snap-in" or "quick-load" movement and includes mechanical and mechanical interfaces. to communicate with the other components of the system of the invention. It will be appreciated that the buffers and solutions required to carry out the purification process or step may be provided in at least one bag. Said bag can be positioned inside or outside the downstream unit and is naturally provided with the necessary connections to ensure its connection to the purification unit.
    Said purification means may be a combination of clarification, flocculation, precipitation of cell debris, lipids, host cell proteins, DNA, as well as ultrafiltration, tangential flow filtration aimed at the concentration of the supernatant, or change of conditions chemicals (such as pH, conductivity, ionic strength). Said means can also be a chromatographic means, in a capture mode or in a flow through mode; chromatography can be contemplated both in a packed mode, a monolithic mode, a membrane-based mode or a fluidized mode; as long as the chromatography is carried out in a fluidized mode, it may include the use of conventional media separated by decantation or centrifugation, or (para) magnetic media separated by an external magnetic field. This can be any combination of any of the previously described means.
    Fig. 5 shows an embodiment of the system which is designed for collecting, filtering and purifying at least one cellular product, such as an antibody. The culture unit C is fluidly connected to the downstream unit D via the outlet pipe 5. The culture unit C is as previously described. The outlet tubing 5 directs the supernatant to a filtering means 7. A pump, or collection means, may be provided to collect the supernatant from the bioreactor. The pump can be programmed to begin supernatant collection from a predetermined time period from the start of the culture. The pump may be programmed to collect a predetermined volume of supernatant in an automated continuous mode. The collected supernatant is then directed to a purification means 12 of the downstream unit D. The purified cellular product obtained can be stored in a reservoir connected to the purification means or directed to another downstream component for subsequent applications.
    The selection device may be a chromatography column such as affinity chromatography, ion exchange chromatography (for example anion or cation), hydrophobic interaction chromatography, exclusion-diffusion chromatography (SEC), immunoaffinity chromatography. which is a column filled with an affinity resin, such as anti-IgM resin, Protein A, Protein G, or anti-IgG resin. The anion exchange exploits charge differences between the different products contained in the collected supernatant. The neutrally charged product passes onto the anion exchange chromatography column cartridge without being retained, while charged impurities are retained. The size of the column may vary on the basis of the type of purified protein and / or the volume of the solution from which said protein is to be purified.
    In a preferred embodiment, the purification means, for example, an affinity column, and / or the filtering means are connected to multiple liquid reservoirs. The reservoirs each contain liquid, such as a wash buffer, an elution buffer, or a neutralization solution, for delivery by means of purification and / or filtration means. The purifying means further comprises a pre-purified or pre-sterilized device for pouring liquid from the reservoirs into the chromatography column for example. For example, pre-sterilized valves and tubing that connect the reservoirs to the column can be used.
    Those skilled in the art know the purification using a chromatography column and can be carried out using the appropriate buffers to elute the desired biomolecules. Upon elution of the desired biomolecule, the eluted purified protein may be automatically deposited in a pre-sterilized, disposable collection vessel provided in the downstream unit and removed from the purification means. Alternatively, the eluted purified protein may undergo subsequent automated processing. A purified protein, for example, an antibody, is substantially free of host cell contaminants such as host cell proteins, nucleic acids, and endotoxins.
    In a preferred embodiment, the eluted protein (anti-RSV antibody) is transferred to different solutions. The transfer occurs automatically using a pre-sterilized diafiltration module. Diafiltration is the fractionation process that cleans smaller molecules through a membrane and retains the molecules of interest in the retentate. Diafiltration can be used to remove salts or exchange buffers. In discontinuous diafiltration, the solution is concentrated, and the lost volume is replaced by new buffer. Concentrating a sample at half its volume and adding new buffer four times can remove more than 96% of the salt. In a continuous diafiltration, the sample volume is maintained by the influx of new buffer while the salt and the old buffer are removed. At least 99% of the salt can be removed by adding up to seven volumes of new buffer during continuous diafiltration. Specifically, the diafiltration module is used to further purify the protein (e.g., antibody) and uses the tangential flow filtration principle whereby molecules of greater than 50,000 Daltons (e.g., antibodies such as IgG and IgM) can not pass through the membrane, but small molecules, such as buffers, can pass through. As a result, the diafiltration module can be used to exchange one buffer with another and is a more effective substitute for dialysis. Diafiltration can be used to neutralize the pH and as a concentration step (to concentrate the cell product).
    In a preferred embodiment, the collection means and / or the filtration means and / or the purification means include at least one control device for controlling the circulating medium: unfiltered collected supernatant, filtered supernatant, purified product and elected, etc. The control device may be a probe or a sensor for measuring conductivity and / or pH and / or absorbance at a particular wavelength of said circulating medium. One or more pressure sensors may be included to control the circulating medium pressure with respect to excessive pressures, or to control the pump speed, for example, to maintain the pump speed of the collection means for example at desired pressure.
    In a preferred embodiment, the system is adapted to the desired product. That is, if cells are to be mass-supplied, the system will include a C-cell culture unit and a downstream D-unit in which at least one collection bag is provided. If the filtered cells are to be provided, the system will comprise the cell culture unit and the downstream unit in which a filtering means and at least one collection bag are provided. If a specific protein is to be provided, the system will include the cell culture unit and the downstream unit in which at least one filtering means and purification means are provided.
    In a preferred embodiment, the method further comprises the step of measuring physical and / or chemical parameters of the cell culture and / or culture medium. Said parameters are selected from the group consisting of temperature, pH, salinity, acidity or any combination thereof. The measurements can be made on the culture medium before injection into the bioreactor and / or into the supernatant which is collected from the bioreactor.
    In a preferred embodiment, the method and / or system of the present invention allows an increase in yield of biomolecules, such as monoclonal antibodies, compared to conventional methods. Said yield of biomolecules ranges from 15 to 100 g / l, preferably from 20 to 60 g / l, more preferably from 25 to 50 g / l, more preferably from 30 to 45 g / l, most preferably 35 to 40 g / L of bioreactor or any value within the ranges mentioned.
    In a preferred embodiment, the method and system of the present invention are free of closed loops or recycling loops. This means that the completed culture medium is returned to the bioreactor at no stage of the process as after passing through the downstream unit. This is advantageous because it considerably reduces the risk of contamination. In addition, it simplifies the setup and installation of the system thereby reducing costs.
    In a second aspect, the present invention provides a system for the production of anti-RSV antibodies and / or anti-RSV formulations comprising anti-RSV antibodies. The system includes a cell culture unit and a downstream unit that are fluidly connected to each other. Said cell culture unit comprises at least one perfusion bioreactor, which allows the growth of cells at a density of at least 50 million cells per ml, and a supply means for supplying said bioreactor with a cell medium and a gas or a gas mixture. The system is characterized in that the total volume of the bioreactor is at least 10 liters. In a preferred embodiment, the downstream unit is separated from and positioned outside the cell culture unit.
    In a preferred embodiment, the bioreactor allows high density cell growth. Said density is at least 50 million cells / ml, preferably at least 80 million cells / ml, more preferably at least 100 million cells / ml, most preferably at least 200 million cells / ml. Said density can reach 600, 500, 400 or 300 million cells / ml.
    In a preferred embodiment, the total volume of the bioreactor is at least 10 L, preferably at least 20 L, more preferably at least 30 L, more preferably at least 40 L, most preferably at least 50 L. The total volume of bioreactor is at most 1000 L, preferably at most 900 L, more preferably at most 800 L, even more preferably at most 700 L, most preferably 500 L. Further preferred embodiment, the total volume of bioreactor is at most 400 L, preferably at most 300 L, more preferably at most 250 L, most preferably at most 100 L. The total volume of bioreactor and bioreactor it - Even according to the invention are smaller compared to conventional bioreactors used for high cell density culture. This is advantageous in terms of the space required for the system and for ease of use.
    In a preferred embodiment, the system is implemented in a small-scale cabinet that can be a transportable room or a clean transportable room. Preferably, the dimensions of the small-scale cabinet are 0.8 □ 1.6 □ 1.8 m3. The system according to one embodiment of the invention can be placed in a transportable clean room. The cell culture unit and the downstream unit are physically distinct, but designed to be placed together in a transportable chamber (e.g., adjacent to each other). Preferably, the cell culture unit and / or the downstream unit can transfer data and coordinate the activity between them using methods known in the art as a communication port (for example, an infrared communication port). , a desktop or laptop, etc.). The downstream unit can be placed next to the cell culture unit towards the end of the production period, or before. At least one tubing line from each unit fluidly connects said units to each other. The operator initiates the culture process and / or the collection process and / or the purification process via a user interface such as a touch screen interface on the transportable chamber and / or the culture unit of cells.
    Preferably, the operating temperature of the cell culture unit is between 20 ° C and 40 ° C, more preferably between 25 ° C and 37 ° C. The operating temperature of the downstream unit may be between 0 ° C and 25 ° C, more preferably between 1 ° C and 20 ° C, even more preferably between 2 ° C and 10 ° C, most preferably about 4 ° C. The temperature of the two units is maintained by cooling and / or heating units and the maintenance of the temperature can be checked by sensors. The integration of components, functions and operations greatly reduces the labor and cost required to produce cells and / or a product derived from cells. The integrated system reduces the preparation and loading time and reduces the number of operator-induced errors that can cause a failure. Process sequencing reduces the operator time required and allows sequential operations to be automatic. The modularization of functions in a cell culture unit and a purification unit allows for higher equipment utilization and lower costs. The cell culture unit enables the production of cell-derived cells and products in a closed, self-sustaining environment. The unit may comprise at least one bioreactor for cells and / or their product expansion with minimal need for interaction by a technician. The bioreactor may be attached to the system in a fixed manner, or may be removably attached to the system.
    The bioreactor used in the method and / or system of the invention may be any type of bioreactor that allows high density cell cultures. The said bioreactor is preferably an infusion bioreactor. The said bioreactor may be provided with supports such as fibers, microfibers, hollow fibers or hollow microfibres. Alternatively, these carriers may be suspended microbeads, in a packed bed or in a fluidized mode. The carriers provide an excellent substrate for cells to grow on. Preferably, the bioreactor comprises microcarriers, preferably polyester microfiber carriers. Preferably, the microfiber supports are biologically compatible. Preferably, they are nonwoven polyester supports. After inoculation of the bioreactor with cells, the cell culture unit follows preprogrammed and automated processes to deliver culture media to the bioreactor and / or maintain pH and / or maintain temperature. Standard or single cell culture growth parameters can be programmed, so that various cell types can be expanded and cells or cell products can be collected in an efficient, reproducible manner with minimal risk of damage. 'human error. In a further preferred embodiment, said supports have been plasma treated to render them hydrophilic. Cells will attach to media as a 3D growth substrate. During protein production, the supernatant may become loaded with the desired end product. By supernatant, reference is made to the culture medium that is inside the bioreactor during cell culture which comprises the cultured cells and / or the cell product.
    Preferably, the supports present in the bioreactor provide a cell growth area of at least 1000 square meters (m2), preferably at least 1200 square meters, more preferably at least 1500 square meters, more preferably at least 1 square meters. 800 m2. The carriers provide a cell growth area of at most 3,000 m2, more preferably at most 2,800 m2, more preferably at most 2,500 m2, most preferably at most 2,200 m2. Preferably, the cell growth area provided by the supports is about 2,000 m2.
    In a preferred embodiment, the bioreactor used in the method and / or the system of the invention is a small bioreactor. Said bioreactor may be a circular bioreactor having a diameter of at least 30 cm, preferably at least 40 cm and at most 70 cm, preferably at most 60 cm, more preferably at most 50 cm. Said bioreactor may also be a rectangular or square bioreactor having a height of at least 40 cm, preferably at least 50 cm, more preferably at least 60 cm and at most 110 cm, preferably at most 100 cm, more preferably not more than 80 cm, most preferably not more than 70 cm. The width of said rectangular or square bioreactor is at least 40 cm, preferably at least 50 cm, more preferably at least 60 cm and at most 100 cm, preferably at most 90 cm, more preferably at most 80 cm, most preferably at most 70 cm.
    The bioreactor can be rotated or moved to thereby increase oxygen transfer and provide gas balance in said bioreactor. This makes it possible to direct cultures into a bioreactor that is sensor-free thereby providing a simple and less complicated bioreactor plant compared to prior art bioreactors. In addition, the use of a bioreactor free of sensors allows a considerable reduction in the risk of contamination. Moving the bioreactor further improves cell collection. Indeed, collecting cells from a bioreactor containing supports such as fibers or microfiber bioreactors has been difficult to accomplish. In a classical way; the cells are sticky and attach to the supports or other cells and form aggregates. Movement of the bioreactor forces the free cells thereby providing increased cell harvesting efficiency at high cell viabilities without the use of chemical or enzymatic release additives. The bioreactor may have a rigid or non-rigid outer body. A rigid outer body allows the bioreactor shell to be flexed causing movement of microfibers. This movement enhances the release of cells that have attached to the bioreactor matrix side.
    In a preferred embodiment, the bioreactor is a bioreactor, an infusion. Preferably, the bioreactor is provided with a single inlet. More preferably, gas and culture medium are introduced into the bioreactor by the same admission. Infusion of gas and culture medium into the bioreactor via a single inlet minimizes the risk of contamination as only one inlet of the bioreactor must be connected to an infusion line. In addition, the bioreactor is thus provided with an easy connection and disconnection system to the infusion line thereby simplifying its separation from the system if the bioreactor needs to be replaced for example. An example of a suitable bioreactor for use in the method and / or system of the invention is shown in Figure 1. Bioreactor 1 is an infusion bioreactor having a donut shape and is approximately half filled with culture medium 2 during cell culture.
    Preferably, the bioreactor is provided with at least one inlet for introducing gas and / or culture medium and at least one outlet for collecting the culture product and / or the medium contained in the bioreactor. At least one inlet manifold is provided for fluidically connecting the bioreactor via its inlet to a culture medium reservoir and / or a gaseous source. At least one outlet pipe is provided to fluidly connect the bioreactor, via its outlet, to a downstream unit and / or any other device.
    In a preferred embodiment, the bioreactor can be releasably connected to a container of cell culture medium. The culture medium is provided in the bioreactor inlet using at least one pump. Preferably, the medium is preheated to a temperature between 25 ° C and 37 ° C and mixed before transfer to the bioreactor. This ensures that the cells will not perceive heat shock by coming into contact with the new medium (which would negatively affect their growth) as well as ensuring that all the nutrients in the medium are mixed and present in the required quantities . The medium may be a liquid comprising a well-defined mixture of salts, amino acids, vitamins and one or more protein growth factors. The culture medium is used to deliver nutrients to the cell and, conversely, to remove or prevent a toxic accumulation of metabolic waste.
    Gas is also provided as pure oxygen or a gaseous mixture comprising oxygen through the inlet of the bioreactor. Oxygen is an essential requirement for the normal growth of mammalian cells. Preferably, said gas or gas mixture is supplied under pressure. In one embodiment, the cells will be exposed to dissolved oxygen concentrations of 300 μΜ or less (160 mmHg partial pressure), preferably less than 200 μΜ, most preferably 20 to 150 μΜ.
    In a preferred embodiment, a gas or mixture of gases and a culture medium will be mixed before being supplied to the bioreactor. Thus, the mixture of gas or gas mixture and culture medium is provided via a single supply line. This provides an advantage in that a cell medium having an optimal oxygen concentration is directly supplied to the cells. In a further preferred embodiment, said gas or gas mixture is selected from air or oxygen. Preferably, air is used. Air should be viewed as a gaseous mixture comprising approximately 78% nitrogen, 21% oxygen and argon and carbon dioxide. The supply of air instead of pure oxygen or oxygen-enriched atmosphere has the advantage that the system using the process may be free of highly concentrated oxygen supply units, which may furthermore involve a danger of oxygen deficiency. explosion or fire.
    The low solubility of oxygen in an aqueous medium (such as a cell culture medium) relative to its rate of consumption causes its feed rate to be a limiting factor for cell growth. In general, the oxygen transfer rate in a fermentation device or a bioreactor is described by: OTR = Ki_a (Cgaz-Cliq), where OTR = oxygen transfer rate in pmol 02 l ^ h'1; KLa = is the oxygen transfer coefficient in h "1;
    Cgaz = concentration 02 (equilibrium) in gaseous phase in μΜ;
    Ciiq = concentration 02 in the liquid phase in μΜ
    Preferably, the oxygen transfer coefficient (KLa) in the current process is at least 20 h -1, preferably at least 30 h -1, more preferably at least 35 h -1. oxygen is at most 100 h -1, preferably at most 50 h -1, more preferably at most 40 h -1.
    A high oxygen transfer coefficient and therefore also a high OTR will have a positive influence on cell growth / health and thus on the desired end product yield. The inventors of the current method have found that an oxygen transfer coefficient as previously defined is particularly advantageous in terms of product yield, even using a rather small amount of starting cell culture.
    In a preferred embodiment, the system bioreactor and / or the method of the invention comprise supports and are subject to movement. The carriers and movement synergistically increase the oxygen transfer coefficient in the bioreactor. Movement of the bioreactor, which is at least partially filled with the culture medium, causes a portion of the supports to move from a liquid phase, in which they are in contact with the culture medium, to a gaseous phase, wherein they are not in contact with said medium. This oxygen transfer rate is increased at least 10-fold in comparison with prior art bioreactors.
    In a particular embodiment, the system is provided with the necessary and appropriate connections to divert cell culture waste into a waste container.
    The system bioreactor can be fluidly connected to at least one downstream unit. In a preferred embodiment, the downstream unit comprises a plug-in means selected from the group comprising at least one filtration means, at least one collection means, at least one dialysis means, at least one biomolecule purification means. and at least one protein concentration unit or any combination thereof.
    In a preferred embodiment, the downstream unit comprises at least one collection means which is provided with at least one inlet and at least one outlet. Said means of the downstream unit may be connected to the cell culture unit of the system. Preferably the connection is made by connecting the bioreactor outlet tubing to said collection means. The collection means comprises at least one tubing for directing the collected supernatant to another component of the downstream unit. The collection means further comprises at least one pump for extracting the supernatant from the bioreactor.
    In a preferred embodiment, the downstream unit comprises at least one filtration means which is provided with at least one inlet and at least one outlet. Said means may be fluidly connected to the bioreactor via its outlet pipe or connected to fluid to the collection means of the downstream unit. Preferably, the filtering means comprises a filter which selectively retains molecules based on their Dalton mass, for example. The filtration means may include viral hollow filters that can be used to filter and remove virus particles from the supernatant. In this case, viral filtration works on the principle of size exclusion. When a protein solution with possible viral contamination is introduced into these hollow filters, the smaller proteins enter the filter wall and make their way to the outside of the filter while the larger virus particles are retained.
    In a preferred embodiment, the downstream unit comprises at least one purification means which is provided with at least one inlet and at least one outlet. Said means may be fluidly connected to the bioreactor via its outlet pipe or fluid connected to the collection means or filtering means of the downstream unit. Preferably, the purification means comprises at least one selection device as previously described.
    In a preferred embodiment, the system comprises a cell culture unit and a downstream unit. The cell culture unit comprises at least one bioreactor for culturing cells. Said bioreactor is connected to a reservoir of culture medium to receive culture medium. To connect the cell culture unit to a downstream unit or other unit or device, at least one outlet tubing attached to an outlet of the bioreactor is provided. Said outlet pipe is suitable for being connected to the intake of collecting means, to the admission of filtering means or to the admission of purification means of a downstream unit thus connecting the two units to the fluid. one to another. In a further preferred embodiment, the bioreactor outlet tubing is connected to the collection means inlet. The collection means outlet is connected to a filtration means inlet and the filtration means outlet is connected to the purification means inlet.
    Those skilled in the art will appreciate that the necessary tubing and / or pump can be provided within the system to achieve the fluid connection between the different compartments of the cell culture unit and / or the downstream unit. In addition, the system may be provided with a plurality of switching valves used to route the fluids between said different compartments. In addition, software may be provided for rotating the system and method according to one embodiment of the invention.
    The method and / or system of the present invention can be used for the cultivation of any cell line and / or for the production of any desired protein and peptide. Possible cultured cell lines are Vero cells, CHO cells, COS cells, 293T cells, HeLa cells, Hep-2 cells, MCF-7 cells, U373 cells or any other cell line. Preferably, CHO cells are used.
    The method and system of the present invention are particularly useful for the production of biologically similar antibodies. The term "biologically similar antibodies" should be understood as "generic" versions of "native" antibodies that have the same amino acid sequence as these "native" antibodies, but which are produced at from different clones and / or by different manufacturing processes.
    The method and / or system can be used for the production of: - anti-inflammatory biomolecules or any antibodies such as infliximab, adalimumab, basiliximab, daclizymab, omalizumab, palivizumab and abciximab - anti-cancer biomolecules such as gemtuzumab, alemtuzumab , rituximab, transuzumab, nimotuzumab, cetuximab, bevacizumab, and formulations thereof.
    Preferably, the method and / or the system are used for the production of anti-RSV formulations. More preferably, such formulations include palivizumab, motavizumab or MEDI-557.
    It is believed that the present invention is not limited to any of the embodiments previously described and that certain modifications may be added to the example of manufacture shown without re-evaluation of the appended claims. The invention is further described by the following non-limiting examples which further illustrate the invention and are not intended to, nor should be construed to limit, the scope of the invention.
    Example
    Production of a vaccine based on RSV antibodies
    The methodology and system of the current invention have been used for the production of a vaccine based on RSV antibodies. Preferably, liquid formulations of a humanized monoclonal antibody that neutralizes a broad range of RSV (Respiratory Syncytial Virus) isolates. In particular, the current invention can be used to produce liquid formulations of SYNAGIS®, or an antigen-binding fragment thereof.
    The amino acid sequence of SYNAGIS® is disclosed, for example, in Johnson et al., 1997, J. Infectious Disease 176: 1215-1224 and in U.S. Patent No. 5,824,307. The properties and uses of SYNAGIS Are also disclosed, for example, in other applications, see, for example, US Patent Application Serial No. 09 / 724,396 filed November 28, 2000; U.S. Patent Application Serial No. 09 / 996,265 filed November 28, 2001 and U.S. Patent Application Serial No. 10 / 403,180 filed March 31, 2003, all of which, and particularly the amino acid sequence of SYNAGIS®, are incorporated. in this document by reference.
    In order to prepare the liquid formulations, the following steps have been carried out: the cultivation of cells, preferably CHO cells according to the method and the system of the current invention. Stable cell lines expressing the desired antibody were used; the purification of the antibody from the conditioned medium by chromatography, and the concentration of a fraction containing the purified SYNAGIS® at a final antibody concentration of approximately 15 mg / ml, approximately 20 mg / ml, approximately 30 mg / ml, about 40 mg / ml, about 50 mg / ml, about 60 mg / ml, about 70 mg / ml, about 80 mg / ml, about 90 mg / ml, about 100 mg / ml, about 150 mg / ml, about 200 mg / ml, about 250 mg / ml, or about 300 mg / ml using a semipermeable membrane having an appropriate molecular weight (MW) cutoff (eg, 30 kD cutoff for whole antibody molecules and F (ab ') 2 fragments, and 10 kD cleavage for antibody fragments, such as Fab fragments) and by diafiltering the concentrated antibody fraction in the formulation buffer using the same membrane.
    Liquid formulations comprising the antibody have been prepared as unit dosage forms by preparing a vial containing an aliquot of the liquid formulation for single use. For example, a unit dosage per vial may contain 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 15 ml, or 20 ml of different concentrations of SYNAGIS® or an antigen-binding fragment thereof ranging from a concentration of about 15 mg / ml to about 300 mg / ml of SYNAGIS® or an antigen-binding fragment thereof that binds immunospecifically to an RSV. Optionally, these preparations were adjusted to a desired concentration by adding a sterile diluent to each vial.
    The liquid formulations of the present invention have been sterilized by various sterilization methods, including sterile filtration, radiation, etc. The diafiltered antibody formulation was sterilized by filter with a 0.2 or 0.22 microns pre-sterilized filter. The sterilized liquid formulations of the present invention may be administered to a subject to prevent, treat, manage, or ameliorate an RSV infection or one or more symptoms thereof.
    Optionally, the formulations can be lyophilized. Thus, the invention encompasses the freeze-dried forms of the formulations of the invention although such freeze-dried formulations are unnecessary and thus not preferred. The current example may also be applied to other well-known antibody-based formulations such as, but not limited to, infliximab, adalimumab, basiliximab, daclizymab, omalizumab, gemtuzumab, alemtuzumab, rituximab, transuzumab, nimotuzumab, cetuximab, bevacizumab , abciximab, motavizumab, or MEDI-557.
    权利要求:
    Claims (15)
    [1]
    An integrated automated method for producing antibodies against Respiratory Syncytial Virus (RSV) comprising: a. culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor to a culture medium feed and a gas or gas mixture; b. fluid connection of said bioreactor with a downstream unit; and c. cell growth at a density of at least 50 million cells per ml; wherein the total volume of the bioreactor is at least 10 liters and not more than 900 L.
    [2]
    2. The method of claim 1, wherein the total volume of bioreactor is at most 800 L, preferably at most 700 L, more preferably at most 500 L.
    [3]
    The method of any of the preceding claims, wherein said culture medium and the gas or gas mixture are supplied to said bioreactor through a single feed line.
    [4]
    4. A process according to any one of the preceding claims, wherein the oxygen transfer coefficient (kLa) in the bioreactor is at least 20 h -1.
    [5]
    A method according to any one of the preceding claims, wherein said downstream unit receives supplemented culture medium from said continuous mode bioreactor, said supplemented culture medium comprises culture medium and / or cultured cells and / or products of said cultured cells comprising proteins, peptides and / or any other cell biomolecules derived from cell lysis such as cell membranes.
    [6]
    The method of any of the preceding claims, wherein said downstream unit receives not more than 1000 ml / min of supplemented culture medium from said bioreactor.
    [7]
    A method according to any one of the preceding claims, wherein the completed culture medium received by the downstream unit undergoes at least one process selected from the group consisting of filtration, collection, dialysis, purification of biomolecules and protein concentration or any combination of these.
    [8]
    The method of any of the preceding claims, wherein said bioreactor is an infusion bioreactor or supported bioreactor providing a cell growth area of at least 1000 m2.
    [9]
    9. A system for the production of antibodies against the Respiratory Syncytial Virus (RSV), comprising a cell culture unit and a downstream unit which are fluidly connected to each other, said cell culture unit comprises at least one less an infusion bioreactor, which allows the growth of cells at a density of at least 50 million cells per ml, and a supply means for supplying said bioreactor in the middle of the cell and in gas or gas mixture, characterized in that the total volume of the bioreactor is at least 10 liters and not more than 900 L.
    [10]
    The system of claim 9, wherein the total volume of bioreactor is at most 800 L, preferably at most 700 L, more preferably at most 500 L.
    [11]
    The system of any of claims 9 and 10, wherein the bioreactor is an infusion bioreactor.
    [12]
    12. System according to any one of claims 9 to 11, wherein said bioreactor is provided with supports.
    [13]
    The system of claim 12, wherein said supports provide a cell growth area of at least 1000 m2.
    [14]
    The system according to any one of claims 9 to 13, wherein said downstream unit comprises a plug-in means selected from the group comprising at least one filtration means, at least one collection means, at least one dialysis means, at least one biomolecule purification means and at least one protein concentration unit or any combination thereof.
    [15]
    15. System according to any one of claims 9 to 14, wherein said system is implemented in a transportable chamber, suitable for a clean transportable room.
    类似技术:
    公开号 | 公开日 | 专利标题
    BE1023557B1|2017-05-03|SYSTEM, APPARATUS AND METHOD FOR PRODUCING BIOMOLECULES
    BE1022439B1|2016-03-30|APPARATUS SYSTEM AND METHOD FOR PRODUCING BIOMOLECULES
    Kalyanpur2002|Downstream processing in the biotechnology industry
    JP6605504B2|2019-11-13|Ultrafiltration unit for continuous exchange of buffers or media from protein solutions
    TWI643865B|2018-12-11|Antibody purification method
    TW201221641A|2012-06-01|Processes for purification of proteins
    KR20140059753A|2014-05-16|Continuous processing methods for biological products
    ES2346673T5|2018-02-15|Process to obtain antibodies
    WO2014004281A1|2014-01-03|Purification of biological molecules
    JP6951341B2|2021-10-20|Tangier flow filtration process for concentrating biomolecular solutions
    CA2754393C|2015-10-27|Membrane evaporation for generating highly concentrated protein therapeutics
    TW201522363A|2015-06-16|Continuous multistep process for purifying antibodies
    US20220017850A1|2022-01-20|System, apparatus and method for the production of cells and/or cell products
    BE1022441B1|2016-03-30|SYSTEM, APPARATUS AND METHOD FOR PRODUCING BIOMOLECULES
    Zydney2021|New developments in membranes for bioprocessing–a review
    Arunkumar et al.2017|Investigation of single-pass tangential flow filtration | as an inline concentration step for cell culture harvest
    KR20190135489A|2019-12-06|Cell Culture Purification
    CN108883368B|2021-12-31|Method for treating solutions of biomolecules
    BE1022269B1|2016-03-08|System, apparatus and method for the production of cells and / or cellular products
    TWI753216B|2022-01-21|Process of and system for using continuous diafiltration by means of tank cycling
    Behera et al.2020|Downstream Processes
    Bhiman2016|Optimisation of ultrafiltration for human serum albumin at NBI
    同族专利:
    公开号 | 公开日
    BE1022441A1|2016-03-30|
    WO2015118149A1|2015-08-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5824307A|1991-12-23|1998-10-20|Medimmune, Inc.|Human-murine chimeric antibodies against respiratory syncytial virus|
    US8026096B1|1998-10-08|2011-09-27|Protein Sciences Corporation|In vivo active erythropoietin produced in insect cells|
    EP1175931A1|2000-07-25|2002-01-30|Computer Cell Culture Center S.A.|Integration of high cell density bioreactor operation with ultra fast on-line downstream processing|
    US6855493B2|2000-11-28|2005-02-15|Medimmune, Inc.|Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment|
    AU2013203461B2|2004-03-05|2016-03-17|Patheon Holdings I B.V.|Process for cell culturing by continuous perfusion and alternating tangential flow|
    US20090042253A1|2007-08-09|2009-02-12|Wyeth|Use of perfusion to enhance production of fed-batch cell culture in bioreactors|WO2015148704A1|2014-03-25|2015-10-01|Terumo Bct, Inc.|Passive replacement of media|
    US11104874B2|2016-06-07|2021-08-31|Terumo Bct, Inc.|Coating a bioreactor|
    法律状态:
    2019-12-13| RC| Pledge established (pawning)|Free format text: DETAILS PLEDGE: RIGHT OF PLEDGE, ETABLI Name of requester: EUROPEAN INVESTMENT BANK Effective date: 20191017 |
    2020-05-29| PD| Change of ownership|Owner name: UNIVERCELLS TECHNONOLOGIES S.A.; BE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION Effective date: 20200407 |
    优先权:
    申请号 | 申请日 | 专利标题
    EP14154430|2014-02-10|
    EP14154430.4|2014-02-10|
    [返回顶部]